Inflammatory bone destruction and osteoimmunology

被引:210
作者
Takayanagi, H
机构
[1] Tokyo Med & Dent Univ, Dept Cell Signaling, Grad Sch,Bunkyo Ku, Ctr Excellence,Program Frontier Res Mol Destruct, Tokyo 1138549, Japan
[2] Japan Sci & Techno Agcy, SORST, Kawaguchi, Saitama, Japan
关键词
arthritis; osteoclast; osteoimmunology; receptor activator of nuclear factor-kappa B ligand;
D O I
10.1111/j.1600-0765.2005.00814.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objectives: The metabolism of hard tissue is influenced by the immune system. Research into the bone destruction associated with inflammatory diseases such as periodontal disease and rheumatoid arthritis has highlighted the importance of the interplay of the immune and skeletal systems. This interdisciplinary research field, called 'osteoimmunology', has become increasingly important for each system by itself as well as the biology linking them. The history and recent progress of this field are reviewed. Material & Methods: 'Osteoimmunology' was coined to describe the pioneering work on the T-cell regulation of osteoclastogenesis by the receptor activator of nuclear factor-kappa B ligand (RANKL) and interferon (IFN)-gamma. Accumulating evidence suggests that the immune and skeletal systems share not only cytokines but also various signaling molecules, transcription factors and membrane receptors. The contribution of T cells to the pathogenesis of inflammatory bone destruction is discussed, and our recent findings are summarized to illustrate how the osteoimmunological network functions. Results: RANKL is an osteoclastogenic cytokine that links bone and the immune system. Immunomodulatory cytokines such as IFNs also participate in the regulation of RANKL signaling and inflammatory bone loss. The transcription factor nuclear factor of activated T cells c1 (NFATc1) has been identified as a master switch regulator of osteoclastogenesis. In addition, immunoglobulin-like receptors are critically involved in bone homeostasis. Conclusion: Bone turns out to be a dynamic tissue that is constantly renewed, where the immune system participates to a hitherto unexpected extent. This emerging field will be of great importance to a better understanding and treatment of diseases of the skeletal and immune systems, as well as to the fundamental biology underpinning both.
引用
收藏
页码:287 / 293
页数:7
相关论文
共 52 条
[41]   Mechanistic insight into osteoclast differentiation in osteolmmunology [J].
Takayanagi, H .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2005, 83 (03) :170-179
[42]   A new mechanism of bone destruction in rheumatoid arthritis: Synovial fibroblasts induce osteoclastogenesis [J].
Takayanagi, H ;
Oda, H ;
Yamamoto, S ;
Kawaguchi, H ;
Tanaka, S ;
Nishikawa, T ;
Koshihara, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 240 (02) :279-286
[43]   RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β [J].
Takayanagi, H ;
Kim, S ;
Matsuo, K ;
Suzuki, H ;
Suzuki, T ;
Sato, K ;
Yokochi, T ;
Oda, H ;
Nakamura, K ;
Ida, N ;
Wagner, EF ;
Taniguchi, T .
NATURE, 2002, 416 (6882) :744-749
[44]   Signaling crosstalk between RANKL and interferons in osteoclast differentiation [J].
Takayanagi, Hiroshi ;
Kim, Sunhwa ;
Taniguchi, Tadatsugu .
ARTHRITIS RESEARCH & THERAPY, 2002, 4 (Suppl 3) :S227-S232
[45]   Postmenopausal osteoporosis, T cells, and immune dysfunction [J].
Teitelbaum, SL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (48) :16711-16712
[46]   RANK-L AND RANK: T cells, bone loss, and mammalian evolution [J].
Theill, LE ;
Boyle, WJ ;
Penninger, JM .
ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 :795-823
[47]   The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-κB ligand-stimulated induction of nuclear factor of activated T cells c1 [J].
Urushibara, M ;
Takayanagi, H ;
Koga, T ;
Kim, S ;
Isobe, M ;
Morishita, Y ;
Nakagawa, T ;
Löeffler, M ;
Kodama, T ;
Kurosawa, H ;
Taniguchi, T .
ARTHRITIS AND RHEUMATISM, 2004, 50 (03) :794-804
[48]  
Vermeire K, 1997, J IMMUNOL, V158, P5507
[49]   TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells [J].
Wong, BR ;
Rho, JR ;
Arron, J ;
Robinson, E ;
Orlinick, J ;
Chao, M ;
Kalachikov, S ;
Cayani, E ;
Bartlett, FS ;
Frankel, WN ;
Lee, SY ;
Choi, YW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (40) :25190-25194
[50]   TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src [J].
Wong, BR ;
Besser, D ;
Kim, N ;
Arron, JR ;
Vologodskaia, M ;
Hanafusa, H ;
Choi, Y .
MOLECULAR CELL, 1999, 4 (06) :1041-1049